401 related articles for article (PubMed ID: 31563999)
1. Multifunctional nanomedicines for targeting epidermal growth factor receptor in colorectal cancer.
Akbarzadeh Khiavi M; Safary A; Barar J; Ajoolabady A; Somi MH; Omidi Y
Cell Mol Life Sci; 2020 Mar; 77(6):997-1019. PubMed ID: 31563999
[TBL] [Abstract][Full Text] [Related]
2. Smart stimuli-responsive biopolymeric nanomedicines for targeted therapy of solid tumors.
Fathi M; Abdolahinia ED; Barar J; Omidi Y
Nanomedicine (Lond); 2020 Sep; 15(22):2171-2200. PubMed ID: 32912045
[TBL] [Abstract][Full Text] [Related]
3. Receptor-based targeting of engineered nanocarrier against solid tumors: Recent progress and challenges ahead.
Akhter MH; Beg S; Tarique M; Malik A; Afaq S; Choudhry H; Hosawi S
Biochim Biophys Acta Gen Subj; 2021 Feb; 1865(2):129777. PubMed ID: 33130062
[TBL] [Abstract][Full Text] [Related]
4. Active targeting strategy in nanomedicines using anti-EGFR ligands - A promising approach for cancer therapy and diagnosis.
Nguyen PV; Hervé-Aubert K; Chourpa I; Allard-Vannier E
Int J Pharm; 2021 Nov; 609():121134. PubMed ID: 34571073
[TBL] [Abstract][Full Text] [Related]
5. Nanomedicines functionalized with anti-EGFR ligands for active targeting in cancer therapy: Biological strategy, design and quality control.
Nguyen PV; Allard-Vannier E; Chourpa I; Hervé-Aubert K
Int J Pharm; 2021 Aug; 605():120795. PubMed ID: 34119579
[TBL] [Abstract][Full Text] [Related]
6. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
7. DePEGylation strategies to increase cancer nanomedicine efficacy.
Kong L; Campbell F; Kros A
Nanoscale Horiz; 2019 Mar; 4(2):378-387. PubMed ID: 32254090
[TBL] [Abstract][Full Text] [Related]
8. Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment.
Juan A; Cimas FJ; Bravo I; Pandiella A; Ocaña A; Alonso-Moreno C
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825618
[TBL] [Abstract][Full Text] [Related]
9. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders.
Muthu MS; Singh S
Nanomedicine (Lond); 2009 Jan; 4(1):105-18. PubMed ID: 19093899
[TBL] [Abstract][Full Text] [Related]
10. Peptide ligand-modified nanomedicines for targeting cells at the tumor microenvironment.
David A
Adv Drug Deliv Rev; 2017 Sep; 119():120-142. PubMed ID: 28506743
[TBL] [Abstract][Full Text] [Related]
11. Highly Uniform Synthesis of Selenium Nanoparticles with EGFR Targeting and Tumor Microenvironment-Responsive Ability for Simultaneous Diagnosis and Therapy of Nasopharyngeal Carcinoma.
Huang J; Huang W; Zhang Z; Lin X; Lin H; Peng L; Chen T
ACS Appl Mater Interfaces; 2019 Mar; 11(12):11177-11193. PubMed ID: 30821437
[TBL] [Abstract][Full Text] [Related]
12. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
13. Actively targeted cetuximab conjugated gamma-poly(glutamic acid)-docetaxel nanomedicines for epidermal growth factor receptor over expressing colon cancer cells.
Maya S; Sarmento B; Lakshmanan VK; Menon D; Jayakumar R
J Biomed Nanotechnol; 2014 Aug; 10(8):1416-28. PubMed ID: 25016642
[TBL] [Abstract][Full Text] [Related]
14. Aptamer-guided nanomedicines for anticancer drug delivery.
Alshaer W; Hillaireau H; Fattal E
Adv Drug Deliv Rev; 2018 Sep; 134():122-137. PubMed ID: 30267743
[TBL] [Abstract][Full Text] [Related]
15. Evaluating Nanomedicines: Obstacles and Advancements.
Swierczewska M; Crist RM; McNeil SE
Methods Mol Biol; 2018; 1682():3-16. PubMed ID: 29039088
[TBL] [Abstract][Full Text] [Related]
16. Improving anti-cancer drug delivery performance of magnetic mesoporous silica nanocarriers for more efficient colorectal cancer therapy.
Iranpour S; Bahrami AR; Nekooei S; Sh Saljooghi A; Matin MM
J Nanobiotechnology; 2021 Oct; 19(1):314. PubMed ID: 34641857
[TBL] [Abstract][Full Text] [Related]
17. Active Tumoral/Tumor Environmental Dual-Targeting by Non-Covalently Arming with Trispecific Antibodies or Dual-Bispecific Antibodies on Docetaxel-Loaded mPEGylated Nanocarriers to Enhance Chemotherapeutic Efficacy and Minimize Systemic Toxicity.
Cheng WJ; Lin SY; Chen M; Chen LC; Ho HO; Chuang KH; Sheu MT
Int J Nanomedicine; 2021; 16():4017-4030. PubMed ID: 34140769
[TBL] [Abstract][Full Text] [Related]
18. Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems.
van Elk M; Murphy BP; Eufrásio-da-Silva T; O'Reilly DP; Vermonden T; Hennink WE; Duffy GP; Ruiz-Hernández E
Int J Pharm; 2016 Dec; 515(1-2):132-164. PubMed ID: 27725268
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor-targeted molecular imaging of colorectal tumors: Detection and treatment evaluation of tumors in animal models.
Miyamoto Y; Muguruma N; Fujimoto S; Okada Y; Kida Y; Nakamura F; Tanaka K; Nakagawa T; Kitamura S; Okamoto K; Miyamoto H; Sato Y; Takayama T
Cancer Sci; 2019 Jun; 110(6):1921-1930. PubMed ID: 30973663
[TBL] [Abstract][Full Text] [Related]
20. Applications of graphene oxide in case of nanomedicines and nanocarriers for biomolecules: review study.
Mousavi SM; Hashemi SA; Ghasemi Y; Amani AM; Babapoor A; Arjmand O
Drug Metab Rev; 2019 Feb; 51(1):12-41. PubMed ID: 30741033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
